



The assessment of serum omentin levels of children with autism spectrum disorder and attention-deficit/hyperactivity disorder

Esra Yürümez, Çağatay Uğur & Mehmet Sertçelik

To cite this article: Esra Yürümez, Çağatay Uğur & Mehmet Sertçelik (2018) The assessment of serum omentin levels of children with autism spectrum disorder and attention-deficit/hyperactivity disorder, Psychiatry and Clinical Psychopharmacology, 28:3, 268-275, DOI: [10.1080/24750573.2017.1421397](https://doi.org/10.1080/24750573.2017.1421397)

To link to this article: <https://doi.org/10.1080/24750573.2017.1421397>



© 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group



Published online: 15 Jan 2018.



Submit your article to this journal [↗](#)



Article views: 561



View related articles [↗](#)



View Crossmark data [↗](#)



Citing articles: 1 View citing articles [↗](#)

The assessment of serum omentin levels of children with autism spectrum disorder and attention-deficit/hyperactivity disorder

Esra Yürümez^a, Çağatay Uğur^b and Mehmet Sertçelik^c

^aDepartment of Child and Adolescent Psychiatry, Ankara University School of Medicine, Ankara, Turkey; ^bDepartment of Child and Adolescent Psychiatry, Ankara Pediatric Hematology–Oncology Training and Research Hospital, Ankara, Turkey; ^cChild and Adolescent Psychiatry Division, Hitit University Çorum Training and Research Hospital, Çorum, Turkey

ABSTRACT

Objectives: We aimed to investigate plasma omentin concentrations in non-obese, drug-free patients with autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) in comparison with healthy volunteers.

Methods: Sixty children with ASD, 60 children with ADHD, and 60 control subjects were recruited. Plasma omentin levels were determined by the enzyme-linked immunosorbent assay.

Results: Plasma levels of omentin (479.0 ng/ml) were found to be significantly higher in patients with ASD (median = 422.6, min/max; 220–800) than in controls (382.5 ng/ml) (median = 322.0, min/max 184–800). No significant difference was found between ADHD and control groups with respect to plasma omentin levels. There was no significant correlation between omentin levels and age of children, ABCL, AbBC, CARS, CPRS, and CTRS scores.

Conclusions: To our knowledge, this is the first study that demonstrated the association between omentin and ASD and ADHD. The present results suggest that plasma omentin levels are increased in non-obese and drug-free patients with ASD when compared with in ADHD and healthy children. The omentin levels in ADHD and ASD need further refinement with larger samples and long-term follow-up periods.

ARTICLE HISTORY

Received 6 October 2017

Accepted 21 December 2017

KEYWORDS

Omentin; autism spectrum disorders (ASD); attention-deficit/hyperactivity disorder (ADHD); adipokines

Introduction

Autism spectrum disorder (ASD) is characterized by developmental abnormalities in social interaction and communication, reciprocity and language use, as well as the occurrence of repetitive and stereotypical behaviours and area of interests [1]. ASD affects nearly 1% of the population worldwide [2,3]. Thus far, a number of genetic, perinatal, and biochemical pathways have been suggested for the aetiology and pathogenesis of this neurodevelopmental disorder, although its exact mechanism remains unclear [4].

Attention-deficit/hyperactivity disorder (ADHD) is characterized by inattention, hyperactivity, and impulsivity. It is accepted to be one of the most common neuropsychiatric disorders, with a global prevalence of around 5–10% in childhood [5]. Similar to ASD, the aetiology of ADHD is not yet clear [6].

Due to the relatively high frequency of both disorders and the inadequacy of the common treatment approaches, which can cause severe economic burdens and negative effects for both children and their family, researchers' interest in the clarification of the aetiologies of these two disorders is increasing. Some studies that have investigated the commonalities of ASD and ADHD have supported the notion that these disorders

have similar biological features [7,8]. Thus, the common aetiological and pathophysiological factors of the two disorders should be investigated systemically.

In recent years, the tissue thought to play a role in the aetiology of psychiatric disorders is the adipose tissue. Adipose tissue is a dynamic structure that plays a role in the regulation of the metabolism in humans by means of secreting adipokines [9]. The adipokines are responsible for several physiological functions, including nutrition, appetite, energy balance, insulin, glucose and lipid metabolism, blood pressure regulation, vascular remodelling, coagulation, and inflammation. There is some evidence supporting the association between the adipokines and anorexia and bulimia nervosa, depression, anxiety disorders, ASDs, ADHD, and schizophrenia [10–15]. However, due to various methodological differences, the results in this regard are inconsistent and hence need to be confirmed. The adipokines are known to have a pro-inflammatory function [16], which is suggested to be one of the biological factors that play a role in the aetiology of both ASD and ADHD [4,7,8].

Prior studies have mostly investigated the levels of adiponectin, leptin, resistin, and ghrelin in neuropsychiatric disorders [17,18] although a few studies have

examined the omentin levels. Omentin is a novel adipocytokine that was first isolated from intestinal paneth cells, although it was later also isolated from cardiac, ovarian, adipose tissue, lungs, and placenta [19]. It is known to be secreted to a greater extent by the cells of the visceral adipose tissue than the subcutaneous adipose tissue [20]. The regulatory mechanisms of omentin in humans are not yet fully understood, but the circulating levels of omentin are known to be negatively associated with metabolic risk factors [21].

Omentin regulates the nitric oxide synthase enzyme and affects the dysfunction of the endothelium [22]. It also antagonizes vasoconstriction due to the effect of noradrenaline through nitric oxide (NO) [23]. NO is a neurotransmitter that regulates many biological processes, including immunity and vasodilatation [24]. The effects of vascular NO are reduced by the presence of free oxygen radicals [25]. These free oxygen radicals occur as a result of various biological reactions, for example, phagocytic activation and synthesis reactions, while an increase in the free radicals causes oxidative stress that may lead to cell damage and endothelial dysfunction [26,27].

There is some evidence to suggest that the oxidative mechanism plays a role in the aetiology of both ASD and ADHD, although the exact biological pathways affecting this mechanism are not yet clear [28–31]. In this context, we hypothesized that the possible effects of omentin on microcirculation and the oxidative system may play a role in the aetiology of ASD and ADHD. Although the relationships between the adipose tissue and various psychiatric disorders have previously been investigated, to the best of our knowledge no prior studies have investigated the omentin levels of children with these two common neurodevelopmental disorders.

Thus the aims of this study were;

- (1) To determine and compare the omentin levels of children with ASD and ADHD,
- (2) To assess the relationship between omentin levels and sociodemographical features and symptom severity of children with ASD and ADHD.

Methods

The ASD group and ADHD group each consisted of 60 Caucasian children aged from 9 to 13 and admitted to the Department of Child and Adolescent Psychiatry, Ankara Pediatric Hematology-Oncology Training and Research Hospital between December 2016 and February 2017. These children were diagnosed with ASD or ADHD according to DSM-5 criteria. They have not taken any medication for at least six months and they were not obese according to body mass indexes

(BMI). The control group consisted of 60 Caucasian healthy children who were matched with clinical groups by gender and age.

The BMI was calculated using the formula kg/m^2 . Normal weight was defined as a BMI between 5th and 85th percentile for age and sex. Centers for Disease Control and Prevention (CDC) data were used for the calculation of the BMI standard deviation score (BMISDS) [32].

All participants and their parents were informed about the study. Written and verbal consents were obtained prior to testing.

The children with mental retardation (Intelligence quotient < 70) were excluded from the groups according to the Wechsler Intelligence Scale for Children – revised and clinical evaluation. Additionally, the children with chronic medical diseases (metabolic, neurological, allergic, or endocrinological diseases), obesity, taking vitamin or any medication in past six months and had an infection in last month were excluded from the study.

Firstly, Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version was applied to the clinical sample. Gökler [33] studied the reliability and validity of Turkish version of this instrument. Conner's parents and teachers rating scales were fulfilled by the parents and teachers of children diagnosed with ADHD. Autism behaviour control checklist and problematic behaviour checklist were filled by parents of children diagnosed with ASD and childhood autism checklist scale was applied to all autistic children by the interviewers.

After obtaining 10 cc venous samples from all participants at 8:00–10:00am, they were kept at room temperature for 20 min and centrifuged at 3000 rpm for 10–20 min and then stored at -20°C until the time of assay. The samples were analysed by using the enzyme-linked immunosorbent assay (ELISA) method which is a biochemistry assay that is used to detect and quantify the presence of the substance. The Human Omentin ELISA kit was used to determine serum concentrations of omentin. The sensitivity of the kit was 0.5 ng/ml. The intra- and inter-assay coefficients of variations were 3.6% and 4.6%, respectively.

This study was approved by the ethic committee of Ankara Pediatric Hematology-Oncology Training and Research Hospital (2015/043).

Instruments

Aberrant Behaviour Checklist (AbBC)

It is an instrument initially used for determining the effects of treatment in children with mental retardation, but it is currently used for measuring the severity of behavioural problems of children with autism [34]. Parents score the problematic behaviour on 58 items of a four-point Likert scale. Turkish validity

and reliability studies were completed by Karabekiroglu and Aman [35].

Childhood Autism Rating Scale (CARS)

It is an autistic behaviour rating scale which consists of 15 items and used for diagnosis and determination of the severity of autism. Each item is a score from 1 to 4. The total score should be minimum 30 if the child has autism [36,37]. The validity and reliability studies for a Turkish sample were completed [38].

Autism Behaviour Checklist (ABCL)

It is a scale used for assessment of autism symptoms and their severity [39]. There are 57 items and 5 categories to determine the behaviours associated with autism. The validity and reliability studies have been conducted on a Turkish sample [40].

Conners' Parent Rating Scale-Revised Long Form (CPRS)

This is a parent-reported scale used for assessment of behavioural problems, ADHD symptoms and their severity of children aged 3–17 [41]. It is a four-point Likert scale and consists of 80 items. Turkish validity and reliability studies of the scale were performed [42].

Conners' Teacher Rating Scale – Revised Long Form (CTRS)

This is a teacher-reported scale used for determining the ADHD symptoms and their severity among ADHD children aged 3–17 [41]. Turkish validity and reliability studies were performed [43].

Statistical analyses

Statistical analyses of the study were performed using the SPSS (version 17.0) statistical program. Shapiro–

Wilk testing was used to assess the distribution of variables. It revealed that there was no normal distribution of parameters except for BMI which used for its comparison among three groups by the use of the ANOVA test. The Kruskal–Wallis test was used to compare the variables among the ASD, ADHD, and control groups, and if needed a Mann–Whitney *U* test was used with the Bonferroni correction, $p < .017$ was accepted as the level of significance. The chi-square test was used to compare the gender which is a dichotomic parameter. To determine the correlation of the continuous variables Spearman's test was used and $p < .05$ was accepted as the significance level.

Results

The study sample was composed of 180 children and 71.1% ($n = 128$) were male and 28.9% ($n = 52$) were female. The three groups (ASD, ADHD, and control) were similar in terms of distribution of gender ($X^2 = 0.379$, $p = .828$), mean age ($p > .05$), and BMI distribution ($p > .05$).

There was found no significant difference between groups with respect to age or education level of mothers and fathers ($p > .05$). Sociodemographical features of children are shown in Table 1.

The omentin levels of groups were compared. The median levels of omentin were 479.0, 385.9, and 382.5 ng/ml for those with ASD, ADHD, and healthy subjects, respectively. The difference between groups was significant ($X^2 = 13.619$, $p = .001$). Dichotomic analysis of the groups with the use of a Mann–Whitney *U* test revealed that the significance in the ratio of omentin was due to the comparison between those with ASD and healthy subjects ($z = -3.043$, $p = .002$), and ASD and ADHD ($z = -3.268$, $p = .001$). The median omentin levels of children with ASD were

Table 1. Sociodemographical findings of participants.

	ASD ($n = 60$) n (%)	ADHD ($n = 60$) n (%)	Healthy ($n = 60$) n (%)	Total ($n = 180$) n (%)	X^2 , F	p
Gender						
Boys	44 (73.3)	43 (71.1)	41 (68.3)	128 (71.1)	0.379	.828
Girls	16 (26.7)	17 (28.3)	19 (31.7)	52 (28.9)		
	Mean $\pm$ SD (min-max)	Mean $\pm$ SD (min-max)	Mean $\pm$ SD (min-max)	Mean $\pm$ SD (min-max)	X^2	p
Age (months)	124.2 $\pm$ 10.4 (103–151)	121.5 $\pm$ 9.4 (99–141)	118.7 $\pm$ 9.1 (96–132)	121.5 $\pm$ 9.9 (96–151)	5.813	.055
BMI (kg/m ²)	21.7 $\pm$ 1.9 (18–25)	21.5 $\pm$ 1.9 (18–25)	21.6 $\pm$ 1.7 (18–25)	21.6 $\pm$ 1.8 (18–25)	0.109	.897
Mothers' age (year)	32.8 $\pm$ 5.1 (23–48)	33.1 $\pm$ 4.4 (23–42)	33.5 (4.1) (27–42)	33.1 (4.5) (23–48)	1.223	.542
Fathers' age (year)	36.5 $\pm$ 5.8 (27–57)	37.1 $\pm$ 4.9 (30–51)	36.9 $\pm$ 5.5 (27–49)	36.8 $\pm$ 5.4 (27–57)	1.078	.583
Mothers' Education (year)	10.3 $\pm$ 3.3 (5–15)	10.9 $\pm$ 3.7 (5–15)	11.0 $\pm$ 3.4 (5–15)	10.8 $\pm$ 3.5 (5–15)	1.625	.444
Fathers' Education (year)	11.7 $\pm$ 3.2 (5–17)	11.1 $\pm$ 3.3 (5–15)	11.2 $\pm$ 3.0 (4–17)	11.3 $\pm$ 3.1 (4–17)	1.574	.455

Note: SD, standard deviation; min, minimum; max, maximum; BMI, body mass index; X^2 , Kruskal–Wallis; F , ANOVA for BMI analysis; ASD, autism spectrum disorder and ADHD, attention–deficit/hyperactivity disorder.

Table 2. Omentin levels of participants.

	Total M (min-max) Mean $\pm$ SD	ASD M (min-max) Mean $\pm$ SD	ADHD M (min-max) Mean $\pm$ SD	Healthy M (min-max) Mean $\pm$ SD	First analysis Kruskal–Wallis $\chi^2=13.619$ $p=.001$	Dual comparisons Mann–Whitney U ASD vs. ADHD: $z=-3.268, p=.001$ ASD vs. Healthy: $z=-3.043, p=.002$ ADHD vs. Healthy: $z=-0.728, p=.476$
Omentin (ng/ml)	327.6 (134–800) 415.8 $\pm$ 201.0	422.6 (220–800) 479.0 $\pm$ 201.2	293.5 (219–800) 385.9 $\pm$ 201.5	322.0 (134–800) 382.5 $\pm$ 188.1		

Note: M, median; min, minimum; max, maximum; SD, standard deviation; ASD, autism spectrum disorder and ADHD, attention-deficit/hyperactivity disorder.

significantly higher (422.6 mg/ml) than those of healthy subjects (322 ng/ml) and children with ADHD (293.5 ng/ml). The omentin levels of children with ADHD and healthy subjects were similar ($z = -0.728, p = .467$) (see Table 2).

The correlation between variables was analysed and shown in Table 3:

- There was no significant correlation between omentin levels and age ($r = -0.014, p = .852$).
- There was no correlation between omentin levels and total scores of ABCL ($r = 0.104, p = .443$), AbBC ($r = -0.055, p = .679$), and CARS ($r = 0.184, p = .159$).
- There was no correlation between omentin levels and CPRS ($r = 0.136, p = .302$) and CTRS ($r = -0.056, p = .669$).
- There was a negative correlation between ABCL scores and age ($r = -0.422, p = .001$).

Discussion

In this study, the omentin levels of children diagnosed with ASD and ADHD were compared with those of healthy subjects (Table 4). The most remarkable finding was the significantly high levels of omentin in the ASD group when compared to the levels in both the ADHD and control groups. However, there was no correlation between the omentin levels and the scores for the CARS and ABCL scales, which are associated with the symptom severity of ASD. Similarly, there was no correlation between the omentin levels and the CPRS and CTRS. Additionally, there no significant correlation was found between omentin levels and age. This result may be related to the insufficient variation of omentin levels and needs to be investigated.

Table 3. Spearman correlation analysis of the variables in ASD group ($n = 60$).

	BMI	Omentin	ABCL	AbBC	CARS
Age	-0.259 0.045	-0.035 0.792	-0.422 0.001	-0.018 0.889	-0.228 0.079
BMI		0.080 0.542	-0.068 0.608	-0.112 0.394	-0.203 0.119
Omentin		1	0.104 0.443	-0.055 0.679	0.184 0.159
ABCL			1	0.149 0.255	0.544 0.000
AbBC				1	0.255 0.049

Note: Significance at the 0.01 level. ABCL, Autism Behavior Checklist; AbBC, Problematic Behavior Checklist and CARS, Childhood Autism Rating Scale.

Being active substances that are thought to have anti-inflammatory functions, the adipokines arise from the adipose tissue and may play a role in the onset of ASD and ADHD as well as other psychiatric diseases [16,44]. In recent years, studies investigating that potential role have mainly focused on the levels of adiponectin, leptin, ghrelin, and resistin, which are the most commonly known adipokines. Such studies have demonstrated that the serum levels of adiponectin are decreased in adult patients with panic disorder [10], major depression [11], schizophrenia [12], obsessive-compulsive disorder [45], and autism [13]. The serum ghrelin levels have been assessed in patients with an eating disorder and major depressive disorder, and increased levels have been reported [14,46].

According to the results of a study that compared the serum adiponectin levels of adult ADHD patients with those of control subjects, the levels of adiponectin were decreased in the ADHD patients [15]. In another study, it was reported that the leptin levels of ADHD children were increased, while the adiponectin levels were decreased [47]. It has been suggested that this result supports the notion that obesity occurs frequently in the ADHD population [48].

The studies that focused on the relation between the adipokines and ASD reported decreased plasma levels of resistin [18] and adiponectin [13] as well as increased levels of leptin [18,49]. The levels of leptin were also assessed in patients diagnosed with ASD who were undergoing risperidone treatment, and it was shown that the increased leptin levels were not associated with the medication [50].

No previous studies have demonstrated changes in the levels of omentin in autism or ADHD patients, although the role of omentin in the aetiology of cardiovascular and endocrinological diseases has been investigated in a number of prior studies [23,51]. Indeed, the relation between omentin and

Table 4. Spearman correlation analysis of the variables in ADHD group ($n = 60$).

	BMI	Omentin	CPRS	CTRS
Age	-0.108 0.412	-0.167 0.203	-0.064 0.625	-0.097 0.459
BMI		-0.056 0.669	0.138 0.294	-0.074 0.577
Omentin		1	0.136 0.302	-0.056 0.669

Note: Significance at 0.01 level. CPRS, Conner's Parent Rating Scale; CTRS, Conner's Teacher Rating Scale and ADHD, attention-deficit/hyperactivity disorder.

neuropsychiatric disorders represents a new area of research and hence there are presently only a few studies concerning this issue.

Increased levels of omentin have been shown in patients with anorexia nervosa [9,52], as well as after weight loss [53] and aerobic training in obese patients with metabolic risk factors [54].

Decreased levels of omentin were observed in diseases characterized by chronic inflammation, for example, Crohn's disease [55], rheumatoid arthritis [56] and Type 1 diabetes mellitus [57] and omentin is suggested to play a role in the regulation of inflammatory processes [23].

The serum levels of omentin have previously been found to be normal in patients diagnosed with major depression, although there was arguably insufficient investigation supporting these results [58]. Yıldırım and colleagues [59] reported that the omentin levels of patients with schizophrenia were significantly lower than those of healthy subjects. Additionally, a negative correlation was detected between the omentin levels and the symptom severity of these patients. It has further been suggested that common aetiological factors at a molecular level (e.g. oxidative stress and immunological mechanisms) that affect similar areas of the brain may play a role in the development of ASD and psychotic disorders [29,60].

Omentin was firstly described in paneth cells and it may be implicated in the defensive mechanisms against pathogenic gut bacteria [61]. Recently, the involvement of both the gut bacteria and dysbiosis in ASD has been well researched in relation to the aetiology of autism [62]. The gut microflora is suggested to have an association with the onset and symptomatology of ASD [63]. The higher serum levels of omentin found in children with ASD may be associated with the role of omentin in the regulation of the intestinal flora. In addition to oxidative stress and immune dysregulation [64], the dysfunction of the mitochondria might play a role in the metabolism of glucose, fatty acids, and energy [65] that occurs in ASD. The dysfunction of the mitochondria is suggested to have possible effects on the functions of the gastrointestinal system due to it being a high-energy organ [4]. Increased levels of omentin have positive effects on insulin sensitivity, oxidative stress, revascularisation, and microcirculation [23] which could point to a protective bias that occurs as a reaction to the differences in the metabolism in ASD patients. The metabolic changes in autism and their relationship with omentin, therefore, require further investigation.

Taking the BMI into consideration, non-obese participants were included in our study and, despite the high levels of omentin found in children with ASD, no correlation was found between the omentin levels and the symptom severity. It is important to note, however, that this result does not provide definitive support

for excluding from consideration the relationship and etiopathogenetic connection between the symptom severity of ASD and the omentin levels. The symptom severity of obese and non-obese children with ASD should thus be investigated further in order to confirm the validity of these results.

In the current study, BMI was used to define obesity among the participants. In order to assess the weight in relation to height, BMI is the most frequently used measure. But there are some disadvantages of using BMI to define paediatric obesity. Because of the variation of BMI distribution according to ethnicity, sex, age, and level of maturity, the significance is more difficult to determine the differences among children and adolescents than within adult populations [66,67]. Statistical approaches for a particular population have often been used due to unclear cut-off values to use in order to define obesity in children and adolescents [68].

In our study, the omentin levels of physically healthy, non-obese, non-smoking, and drug-free participants diagnosed with ASD and ADHD were compared with the omentin levels of the control group. The strengths of the present study include the inclusion of a gender and age-matched control group and the fact that semi-structured clinical interviews were conducted with all the participants. However, the study did have some methodological limitations. First, the participants included in the study were all recruited from one centre. Second, the assessment of the omentin levels was cross-sectional and there was no long-term follow-up period. Hence, it is not clear whether the omentin levels change during growth. Further, the relatively small sample size represents another limitation of this study. Additionally, it has previously been reported that the serum omentin concentrations were higher in women than in men [52], although the serum concentration of omentin has been shown to be negatively correlated with 17 β -oestradiol [56]. In our study, the groups were not compared with each other according to the gender and age of onset of puberty variables. On the other hand, as another limitation, some factors that could be effective on omentin levels, such as fasting [69], physical exercise [70], maternal obesity [71], obstructive sleep apnea syndrome [72], pain [73], and non-obese polycystic ovary syndrome [74], food rituals and nutritional status of children have not been assessed in our study. Thus, these results must be confirmed by other studies with larger samples of different age ranges and by taking these factors into consideration.

Conclusions

The findings of our study seem to suggest the role of omentin in ASD. To the best of our knowledge, this is the first study to investigate the omentin levels of

children with ASD and ADHD. These results may inspire further studies on the aetiology of both ASD and ADHD featuring larger samples and long-term follow-up periods. The relation between the adipose tissue and mental disorders represents a new area of research and there is currently only limited information available on this issue. Biochemical studies concerning the aetiopathogenesis of both ASD and ADHD are needed to develop more effective treatment approaches for these disorders.

Disclosure statement

No potential conflict of interest was reported by the authors.

ORCID

Çağatay Uğur  <http://orcid.org/0000-0003-2368-9018>

Mehmet Sertçelik  <http://orcid.org/0000-0001-7031-3318>

References

- [1] American Psychiatric Association. (2000). *Diagnostic and statistical manual of mental disorders*. (4th ed). (text rev.). Washington, DC: American Psychiatric Association.
- [2] Brugha TS, McManus S, Bankart J, et al. Epidemiology of autism spectrum disorders in adults in the community in England. *Arch Gen Psychiatry*. 2011;68(5):459–465.
- [3] Elsabbagh M, Divan G, Koh YJ, et al. Global prevalence of autism and other pervasive developmental disorders. *Autism Res*. 2012;5(3):160–179.
- [4] Rossignol DA, Frye RE. A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. *Mol Psychiatry*. 2012;17(4):389–401.
- [5] Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and meta-regression analysis. *Am J Psychiatry*. 2007;164(6):942–948.
- [6] Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention deficit hyperactivity disorder. *Biol Psychiatry*. 2005;57(11):1313–1323.
- [7] McGinnis WR. Oxidative stress in autism. *Altern Ther Health Med*. 2004;10(6):22–36.
- [8] Ross BM, McKenzie I, Glen I, et al. Increased levels of ethane, a non-invasive marker of n-3 fatty acid oxidation, in breath of children with attention deficit hyperactivity disorder. *Nutr Neurosci*. 2003;6(5):277–281.
- [9] Oswiecimska J, Suwala A, Swietochowska E, et al. Serum omentin levels in adolescent girls with anorexia nervosa and obesity. *Physiol Res*. 2015;64(5):701–709.
- [10] Unsal C, Hariri AG, Yanartas O, et al. Low plasma adiponectin levels in panic disorder. *J Affect Disord*. 2012;139(3):302–305.
- [11] Leo R, Di Lorenzo G, Tesaro M, et al. Decreased plasma adiponectin concentration in major depression. *Neurosci Lett*. 2006;407(3):211–213.
- [12] Cohn TA, Remington G, Zipursky RB, et al. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. *Can J Psychiatry*. 2006;51(6):382–386.
- [13] Fujita-Shimizu A, Suzuki K, Nakamura K, et al. Decreased serum levels of adiponectin in subjects with autism. *Prog Neuropsychopharmacol Biol Psychiatry*. 2010;34(3):455–458.
- [14] Tanaka M, Nakahara T, Kojima S, et al. Effect of nutritional rehabilitation on circulating ghrelin and growth hormone levels in patients with anorexia nervosa. *Regul Pept*. 2004;122(3):163–168.
- [15] Mavroconstanti T, Halmoy A, Haavik J. Decreased serum levels of adiponectin in adult attention deficit hyperactivity disorder. *Psychiatry Res*. 2014;216(1):123–130.
- [16] Lago F, Dieguez C, Gómez-Reino J. Adipokines as emerging mediators of immune response and inflammation. *Nat Rev Rheumatol*. 2007;3(12):716–724.
- [17] Emül HM, Serteser M, Kurt E, et al. Ghrelin and leptin levels in patients with obsessive-compulsive disorder. *Prog Neuropsychopharmacol Biol Psychiatry*. 2007;31(6):1270–1274.
- [18] Rodrigues DH, Rocha NP, da Cunha Sousa LF, et al. Changes in adipokine levels in autism spectrum disorders. *Neuropsychobiology*. 2014;69(1):6–10.
- [19] Yang RZ, Lee MJ, Hu H, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. *Am J Physiol Endocrinol Metab*. 2006;290(6):1253–1261.
- [20] Ohashi K, Shibata R, Murohara T, et al. Role of anti-inflammatory adipokines in obesity-related diseases. *Trends Endocrinol Metab*. 2014;25(7):348–355.
- [21] Shibata R, Ouchi N, Takahashi R, et al. Omentin as a novel biomarker of metabolic risk factors. *Diabetol Metab Syndr*. 2012;4(1):37.
- [22] Sacks HS, Fain JN. Human epicardial adipose tissue: a review. *Am Heart J*. 2007;153(6):907–917.
- [23] Tan BK, Adya R, Randeve HS. Omentin: a novel link between inflammation, diabetes, and cardiovascular disease. *Trends Cardiovasc Med*. 2010;20(5):143–148.
- [24] Vincent SR. Nitric oxide neurons and neurotransmission. *Prog Neurobiol*. 2010;90(2):246–255.
- [25] Lyall F, Gibson JL, Greer IA, et al. Increased nitrotyrosine in the diabetic placenta: evidence for oxidative stress. *Diabetes Care*. 1998;21(10):1753–1758.
- [26] Förstermann U, Münzel T. Endothelial nitric oxide synthase in vascular disease. *Circulation*. 2006;113(13):1708–1714.
- [27] Förstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. *Nat Clin Pract Cardiovasc Med*. 2008;5(6):338–349.
- [28] James SJ, Melnyk S, Jernigan S, et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. *Am J Med Genet B Neuropsychiatr Genet*. 2006;141(8):947–956.
- [29] Chauhan A, Chauhan V. Oxidative stress in autism. *Pathophysiology*. 2006;13(3):171–181.
- [30] Archana E, Pai P, Prabhu BK, et al. Altered biochemical parameters in saliva of pediatric attention deficit hyperactivity disorder. *Neurochem Res*. 2012;37(2):330–334.
- [31] Bulut M, Selek S, Gergerlioglu HS, et al. Malondialdehyde levels in adult attention-deficit hyperactivity disorder. *J Psychiatry Neurosci*. 2007;32(6):435–438.
- [32] Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. *Adv Data*. 2000;314:1–27.

- [33] Gökler B, Ünal F, Pehlivan Türk B, et al. Reliability and validity of schedule for affective disorders and schizophrenia for school age children-present and lifetime version-Turkish version (K-SADS-PL-T). *Turk J Child Adolesc Ment Health*. 2004;11(3):109–116.
- [34] Aman MG, Singh NN, Stewart AW, et al. Psychometric characteristics of the aberrant behavior checklist. *Am J Ment Defic*. 1985;89:492–502.
- [35] Karabekiroğlu K, Aman MG. Validity of the aberrant behavior checklist in a clinical sample of toddlers. *Child Psychiatry Hum Dev*. 2009;40(1):99–110.
- [36] Schopler, E, Reichler, RJ, & Rothen Renner, B. (2007). *The Childhood Autism Rating Scale (CARS)*. (11th ed). Los Angeles, CA: Western Psychological Services.
- [37] Mesibov GB, Schopler E, Schaffer B, et al. Use of the Childhood Autism Rating Scale with autistic adolescents and adults. *J Am Acad Child Adolesc Psychiatry*. 1989;28(4):538–541.
- [38] Gassaloğlu, SI, Baykara, B, & Avcil, S. (2016). Validity and reliability analysis of Turkish version of Childhood Autism Rating Scale. *Turk Psikiyatri Derg*, 27(4), 266–274.
- [39] Krug DA, Arick JR, Almond PJ. Autism screening instrument for educational planning: an assessment and educational planning system for autism and developmental disabilities: examiner's manual. 2nd ed. Austin (TX): Pro-Ed; 1993.
- [40] Yılmaz-Irmak T, Tekinsav-Sutcu S, Aydin A, et al. Otizm davranış kontrol listesinin (ABC) geçerlik ve güvenilirliğinin incelenmesi (An investigation of validity and reliability of autism behavior checklist, ABC). *J Child Adolesc Ment Health*. 2007;14(1):13–23.
- [41] Conners CK. Conners' Rating Scales-revised: user's manual. Multi-Health Systems, Incorporated; 1997.
- [42] Kaner S, Büyüköztürk Ş, Iseri E, et al. Conners' Parent Rating Scale long form-revised: factor structure, reliability and validity studies. *Turk J Child Adolesc Ment Health*. 2011;18(1):45–58.
- [43] Kaner S, Büyüköztürk S, Iseri E. The validity and reliability study of the Turkish version of Conners' Teacher Rating Scale-revised (CTRS-R). World Psychiatric Association Congress, July 12–16, Istanbul. *Turk Psikiyatri Derg*. 2006;17:227.
- [44] Pan W, Kastin AJ. Adipokines and the blood-brain barrier. *Peptides*. 2007;28(6):1317–1330.
- [45] Ari M, Ozturk OH, Bez Y, et al. Serum adiponectin and resistin levels in patients with obsessive compulsive disorder. *J Affect Disord*. 2012;136(3):979–982.
- [46] Gecici O, Kuloglu M, Atmaca M, et al. High serum leptin levels in depressive disorders with atypical features. *Psychiatry Clin Neurosci*. 2005;59(6):736–738.
- [47] Özcan, Ö, Arslan, M, & Güngör, S. (2015). Plasma leptin, adiponectin, neuropeptide Y levels in drug naive children with ADHD. *J Atten Disord*, 5. (Epub ahead of print).
- [48] Holtkamp K, Konrad K, Müller B, et al. Overweight and obesity in children with attention-deficit/hyperactivity disorder. *Int J Obes*. 2004;28(5):685–689.
- [49] Blardi P, de Lalla A, Ceccatelli L, et al. Variations of plasma leptin and adiponectin levels in autistic patients. *Neurosci Lett*. 2010;479(1):54–57.
- [50] Ashwood P, Kwong C, Hansen R, et al. Brief report: plasma leptin levels are elevated in autism: association with early onset phenotype? *J Autism Dev Disord*. 2008;38(1):169–175.
- [51] Yan P, Liu D, Long M, et al. Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus. *Exp Clin Endocrinol Diabetes*. 2011;119(4):257–263.
- [52] Guo LJ, Jiang TJ, Liao L, et al. Relationship between serum omentin-1 level and bone mineral density in girls with anorexia nervosa. *J Endocrinol Invest*. 2013;36(3):190–194.
- [53] Moreno-Navarrete JM, Catalán V, Ortega F, et al. Circulating omentin concentration increases after weight loss. *Nutr Metab*. 2010;7(1):27–33.
- [54] Saremi A, Asghari M, Ghorbani A. Effects of aerobic training on serum omentin-1 and cardiometabolic risk factors in overweight and obese men. *J Sports Sci*. 2010;28(9):993–998.
- [55] Schäffler A, Schölmerich J, Büchler C. Mechanisms of disease: adipocytokines and visceral adipose tissue-emerging role in intestinal and mesenteric diseases. *Nat Rev Gastroenterol Hepatol*. 2005;2(2):103–111.
- [56] Senolt L, Polanská M, Filková M, et al. Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis. *Ann Rheum Dis*. 2010;69(7):1410–1411.
- [57] Tan BK, Adya R, Farhatullah S, et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome. *Diabetes*. 2008;57(4):801–808.
- [58] Canan F, Yildirim O, Tosun M, et al. Serum levels of omentin are not altered in drug-naïve patients with major depression: a pilot study. *Psychiatr Danub*. 2014;26(1):34–38.
- [59] Yildirim O, Canan F, Tosun M, et al. Plasma omentin levels in drug-free patients with schizophrenia. *Neuropsychobiology*. 2014;69(3):159–164.
- [60] Smaga I, Niedzielska E, Gawlik M, et al. Oxidative stress as an etiological factor and a potential treatment target of psychiatric disorders. Part 2. Depression, anxiety, schizophrenia and autism. *Pharmacol Rep*. 2015;67(3):569–580.
- [61] Komiya T, Tanigawa Y, Hirohashi S. Cloning of the novel gene intelectin, which is expressed in intestinal paneth cells in mice. *Biochem Biophys Res Commun*. 1998;251(3):759–762.
- [62] Tomova A, Husarova V, Lakatosova S, et al. Gastrointestinal microbiota in children with autism in Slovakia. *Physiol. Behav*. 2015;138:179–187.
- [63] De Angelis M, Piccolo M, Vannini L, et al. Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified. *PLoS One*. 2013;8(10):e76993.
- [64] Ming X, Brimacombe M, Chaaban J, et al. Autism spectrum disorders: concurrent clinical disorders. *J Child Neurol*. 2008;23(1):6–13.
- [65] Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. *Dev Med Child Neurol*. 2011;53(9):783–792.
- [66] Eisenmann JC, Heelan KA, Welk GJ. Assessing body composition among 3- to 8-year old children: anthropometry, BIA and BXA. *Obes Res*. 2004;12(10):1633–1640.
- [67] Daniels SR, Khoury PR, Morrison JA. The utility of body mass index as a measure of body fatness in children and adolescents: differences by race and gender. *Pediatrics*. 1997;99(6):804–807.
- [68] Sweeting HN. Measurement and definitions of obesity in childhood and adolescence: a field guide for the uninitiated. *Nutr J*. 2007;6(1):32.

- [69] Wędrychowicz A, Zając A, Pilecki M, et al. Peptides from adipose tissue in mental disorders. *World J Psychiatry*. 2014;4(4):103–111.
- [70] Ouerghi N, Fradj MKB, Bezrati I, et al. Effect of high-intensity interval training on plasma omentin-1 concentration in overweight/obese and normal-weight youth. *Obes Facts*. 2017;10(4):323–331.
- [71] Barker G, Lim R, Georgiou HM, et al. Omentin-1 is decreased in maternal plasma, placenta and adipose tissue of women with pre-existing obesity. *PloS One*. 2012;7(8):e42943.
- [72] Zirlik S, Hildner KM, Targosz A, et al. Melatonin and omentin: influence factors in the obstructive sleep apnoea syndrome. *J Physiol Pharmacol*. 2013;64(3):353–360.
- [73] Harmon JB, Sanders AE, Wilder RS, et al. Circulating omentin-1 and chronic painful temporomandibular disorder. *J Oral Facial Pain Headache*. 2016;30(3):203–209.
- [74] Yang HY, Ma Y, Lu XH, et al. The correlation of plasma omentin-1 with insulin resistance in non-obese polycystic ovary syndrome. *Ann Endocrinol (Paris)*. 2015;76(5):620–627.